Compare Abeona Therapeutics Inc (ABEO) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Enveric Biosciences Inc — how do they compare? Abeona Therapeutics Inc trades at $6.68 (market cap $373.32M), while Enveric Biosciences Inc trades at $1.42 (market cap $5.84M). The key difference: Abeona Therapeutics Inc is far larger — about 63.9× Enveric Biosciences Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | ENVB | |
|---|---|---|
Market Cap | $373.32M | $5.84M |
Sector | Health | Health |
52-Week High | $7.23 | $17.40 |
52-Week Low | $4.17 | $1.28 |
Enterprise Value | $228.22M | $932.52K |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
ENVB trades at $1.48, up 2.07% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, with negative ROE and ROA, yet consistently beat earnings expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies.
The outlook is mixed: strong analyst support (75% buy ratings) and positive clinical updates contrast with deep losses and bearish technicals. Key risks include clinical trial outcomes and cash burn, while institutional financing provides near-term stability. Upside depends on successful drug development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
